Topics

Pfizer's Ibrance combo authorised via the Cancer Drugs Fund for advanced breast cancer

06:42 EST 15 Jan 2020 | Pharmafile

NICE, the drug watchdog for England and Wales, has given its approval for Pfizer’s Ibrance (palbociclib) in combination with AstraZeneca’s Faslodex (fulvestrant) to be made available via the Cancer Drugs Fund as a treatment for advanced breast cancer.

Specifically, the ruling relates to patients whose tumours are hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, and who have already received endocrine therapy.

read more

Original Article: Pfizer's Ibrance combo authorised via the Cancer Drugs Fund for advanced breast cancer

NEXT ARTICLE

More From BioPortfolio on "Pfizer's Ibrance combo authorised via the Cancer Drugs Fund for advanced breast cancer"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...